Author
Listed:
- Despoina Kosmara
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology)
- Sofia Papanikolaou
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology
Biomedical Sciences Research Center “Alexander Fleming”, Institute of Bioinnovation)
- Chrysoula Stathopoulou
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology)
- Dionysios Papamatheakis
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete, Heraklion, Department of Biology)
- Giannis Vatsellas
(Biomedical Research Foundation Academy of Athens, Greek Genome Center)
- Arianna Cimmarrusti
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology)
- Aggelos Banos
(Biomedical Research Foundation Academy of Athens, Center of Clinical, Experimental Surgery and Translational Research)
- Prodromos Sidiropoulos
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology)
- Matthieu D. Lavigne
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB))
- Panayotis Verginis
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete, Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School)
- Dimitrios Boumpas
(Biomedical Research Foundation Academy of Athens, Center of Clinical, Experimental Surgery and Translational Research)
- Charalampos Spilianakis
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete, Heraklion, Department of Biology)
- Dimitris Konstantopoulos
(Biomedical Sciences Research Center “Alexander Fleming”, Institute of Bioinnovation)
- Christoforos Nikolaou
(Biomedical Sciences Research Center “Alexander Fleming”, Institute of Bioinnovation)
- George Bertsias
(Foundation for Research and Technology—Hellas (FORTH), Institute of Molecular Biology and Biotechnology (IMBB)
University of Crete Medical School, Rheumatology and Clinical Immunology)
Abstract
A strong female bias is characteristic of systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease. Here, through an unbiased transcriptome analysis, we report a pronounced female-biased expression of the cohesin complex subunit SMC1A, a genome architectural factor, in monocytes from SLE patients compared to those from healthy individuals or patients with ankylosing spondylitis, a non-sex-biased autoimmune disorder. Integration of SMC1A binding, chromatin activity, and accessibility in lupus-like monocytes reveals extensive SMC1A redistribution to active enhancers of immune/inflammatory genes, inducing their transcription. SLE monocyte transcriptomes demonstrate significant enrichment of female-biased immune/inflammatory genes among SMC1A targets, accompanied by increased secretion of cytokines including IL6, with enhanced SMC1A binding at their enhancers in lupus-like monocytes. Collectively, our study highlights SMC1A as a female-biased chromatin modifier that acquires a specific regulatory function during lupus, accentuating inflammatory pathways and providing mechanistic insights into the female-biased predisposition to SLE and other autoimmune diseases.
Suggested Citation
Despoina Kosmara & Sofia Papanikolaou & Chrysoula Stathopoulou & Dionysios Papamatheakis & Giannis Vatsellas & Arianna Cimmarrusti & Aggelos Banos & Prodromos Sidiropoulos & Matthieu D. Lavigne & Pana, 2025.
"The sex-biased chromatin modifier SMC1A promotes autoimmunity by shaping inflammatory pathways in patients with SLE,"
Nature Communications, Nature, vol. 16(1), pages 1-22, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-65309-7
DOI: 10.1038/s41467-025-65309-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-65309-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.